Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6.6% – Here’s Why

Posted by Tech Dows on Mar 4th, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) traded down 6.6% during mid-day trading on Tuesday . The company traded as low as $6.76 and last traded at $6.89. 183,557 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 1,210,110 shares. The stock had previously closed at $7.38.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock.

Get Our Latest Report on Tonix Pharmaceuticals

Tonix Pharmaceuticals Stock Up 5.7 %

The stock has a market cap of $14.58 million, a PE ratio of 0.00 and a beta of 2.07. The business has a 50 day simple moving average of $23.27 and a 200 day simple moving average of $21.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals during the fourth quarter worth approximately $40,000. Two Sigma Investments LP acquired a new position in Tonix Pharmaceuticals in the 4th quarter valued at $66,000. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth $72,000. Northern Trust Corp bought a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at about $526,000. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.